• Latest Posts

Inhaled mRNA medicines redefine respiratory disease treatment

Affibody and Chiesi Group to develop treatments for respiratory diseases

Positive results for INOVIO recurrent respiratory papillomatosis trial

Poolbeg identifies new potential drug candidates for RSV infections 

ADVERTISEMENT

Watch: Atriva Therapeutics at BIO-Europe

Tetra announce significant results from the study of Onternabez combined with Favipiravir

Licensing agreement signed for C4XD between C4X Discovery and AstraZeneca

First patients dosed with Infex Therapeutics’ RESP-X for chronic respiratory disease

Progress of COPD drug boosted by debt financing of up to $150M

Patents granted for Poolbeg Pharma influenza and respiratory virus infections treatments

ADVERTISEMENT